A serological method’s ability to distinguish treatment regimens by assessing early antibody decline in Chagas patients: insights from E1224 data
Clicks: 1
ID: 325602
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #426 of 427 articles by views in The Journal of infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 427 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
BACKGROUND: No reliable markers exist for parasitological cure in adult patients with chronic Chagas disease. We assessed whether a serological multiplex immunoassay for Trypanosoma cruzi, MultiCruzi, could differentiate the outcomes of treatment regimens. METHODS: This analysis included adults with indeterminate Chagas disease from a randomized trial of E1224. Serum samples at baseline, 6, and 12 months post-treatment with Benznidazole, E1224 regimens, or placebo were tested at three dilutions using MultiCruzi. We calculated the dilution factor at which 50% of reactivity remained (DF50) and used mixed-effects models to assess antibody decline. Log2DF50 slopes compared Benznidazole and E1224 regimens, and pooled data from the BENDITA trials helped define a cut-off for treatment response. FINDINGS: Within six months after treatment, participants exhibited a significantly greater rate of decline in antibody levels compared to the placebo group, contrasting with results from T. cruzi conventional ELISA tests. Our analysis showed a difference in response to benznidazole and to E1224 regimens after twelve months' follow-up, confirming results for benznidazole from BENDITA. Combining data from both trials allowed discrimination of benznidazole and E1224 treatment regimens after six months' follow-up. CONCLUSION: MultiCruzi enables the early assessment of treatment-associated biological responses in adults with Chagas disease, with antibody decline serving as an exploratory pharmacodynamic marker.
| Reference Key |
openalex_W7203764242
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Ursula Saade, Juan Carlos Ramirez, Jasper de Boer, Noelia Anahi Bazan, Franco Mauricio Mangone, Thomas Ramadier, Ivan Scandale, Hans Pottel, Jaime Altcheh, Eric Chatelain, Maan Zrein |
| Journal | The Journal of infectious diseases |
| Year | 2026 |
| DOI |
10.1093/infdis/jiag427
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.